IL13RA2 and neoplasm: Notably, while IL-13Rα1 is ubiquitously expressed in healthy tissues, IL-13Rα2 exhibits tumor-specific overexpression with minimal distribution in normal organs, positioning it as a high-value target for chimeric antigen receptor (CAR) T-cell therapy in PDAC.